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Methods We identified hospitalized persons and deaths in persons diagnosed with pneumonia and influenza (P&I, ICD-10 codes J10-J18) and respiratory and circulatory illness (R&C, codes I00-I99 and J00-J99). We defined the influenza season as the months when the proportion of samples that tested positive for influenza exceeded the annual median. We used hospitalizations and deaths during the influenza off-season to estimate, using linear regression, the number of excess deaths that occurred during the influenza season. To explore whether excess mortality varied by sex and whether people were age <65 or ‡65 years, we used Poisson regression of the influenza-associated rates.
Results During 2002-2009, 2411 P&I and 8527 R&C mean excess deaths occurred annually from May to October. If all of these excess deaths were associated with influenza, the influenzaassociated mortality rate was 6 ⁄ 100 000 person-years (95% CI 4-8 ⁄ 100 000 person-years for P&I and 21 ⁄ 100 000 person-years (95% CI 12-31 ⁄ 100 000 person-years) for R&C. During 2005-2008, we identified an average of 7868 P&I excess hospitalizations and 22 994 R&C hospitalizations per year, resulting in an influenza-associated hospitalization rate of 2 ⁄ 10 000 person-years (95% CI 1-3 ⁄ 10 000 person-years) for P&I and 6 ⁄ 10 000 personyears (95% CI 3-8 ⁄ 10 000 person-years) for R&C.
Introduction
Influenza is documented as an important cause of deaths and hospitalizations in countries where data are available. [1] [2] [3] Most severe disease occurs in subpopulations at high risk for complications from influenza illness, such as persons aged ‡65 years, persons with preexisting respiratory and circulatory conditions, pregnant women, and very young children. For example, during 1976-2007, persons in the United States aged ‡65 years had substantially higher average influenza-associated mortality rate (66AE1 ⁄ 100 000 person-years) than those aged 19-64 years (1AE5 ⁄ 100 000 person-years) or <19 years (0AE2 ⁄ 100 000 person-years). 1 Such data have helped health authorities target influenza prevention and control campaigns to subpopulations at greatest risk of death and hospitalization. 4 Estimating influenza-associated rates of deaths and hospitalizations often is difficult because physicians do not typically test, diagnose, or report influenza illness. To compensate for these challenges, countries often use multiplier 3 or time-series regression models 5 to estimate the proportion of persons with respiratory illnesses that might be associated with influenza infections. Argentina, for example, has used autoregressive integrated moving average models and pneumonia and influenza (P&I) mortality data to estimate the excess number of P&I deaths during the influenza season. Kusznierz et al. 6 8 To support such investments in the influenza vaccine program and other investments in non-pharmaceutical interventions aimed at preventing respiratory infections, it is useful to better understand the current influenza-associated mortality and hospitalization rates in Argentina. In this study, we used P&I and R&C mortality and hospital discharge data, viral surveillance data, and census data to estimate the excess influenza-associated P&I and R&C deaths during [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] 10 Overall, 51% of all the population was female although there were more women 3 070 579 (62%) than men (1 886 257) aged >65 years.
Determining the timing of the influenza season through surveillance
We used Argentina's influenza surveillance system to identify the timing of the influenza season. In 1997, physicians in Argentina started testing patients with respiratory symptoms for influenza and other respiratory viruses. In 2007, Argentina adopted the PAHO-CDC generic protocol for influenza surveillance. 11 The national influenza and other respiratory virus laboratory surveillance network and three national influenza centers geographically distributed throughout the country tested respiratory samples for influenza virus using immunofluorescence, real-time reverse transcription-polymerase chain reaction, 12 and viral culture. 13, 14 The National Influenza Centers also conducted antigenic characterization from isolated viruses.
We defined the influenza season as the first week when the proportion of respiratory samples that tested positive for influenza was above the median proportion positivity for at least three consecutive weeks that year. To be conservative, we defined the influenza season as the first week when the proportion of respiratory samples being tested for influenza was above the median for at least three consecutive weeks that year through the last week when the proportion of respiratory samples being tested for influenza was above the median. We determined the average start and end of the influenza season during the 2002-2009 to determine when excess respiratory and circulatory deaths and hospitalizations might be attributed to influenza infections. We defined a subtype or type as predominant if it represented >50% of typed or subtyped strains. If two or more subtypes or types were identified during the same season, we considered each a predominant virus if it represented >25% of identified strains.
Observed P&I and R&C deaths and hospitalizations
We identified pneumonia P&I International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes J10-J18 and R&C codes I00-I99 and J00-J99 from PAHO's mortality databases and Argentina's hospitalization databases because we believed a proportion of these deaths and hospitalizations could be associated with influenza illness if they occurred during the influenza season. In Argentina, death certificates are routinely completed on persons who were under medical care before their death. Death certificates were compiled into a mortality database later submitted to PAHO for code verification using PAHO standardized database cleaning protocols. The statistics unit of the Ministerio de Salud de la Nació n also records the ICD-10 code of the primary discharge diagnosis of all persons who seek care government-operated hospitals, the hospital system that serve persons with and without private insurance in Argentina.
Excess influenza-associated P&I and R&C deaths and hospitalizations
We used a linear regression model 5, 15 and fitted a regression line to ICD-10 coded respiratory and circulatory hospitalizations and deaths that occurred during the influenza off-season to estimate the expected number of events during the season and its 95% confidence interval. *We assumed the excess respiratory and circulatory events during the influenza season approximate the totality of the annually influenza-associated mortality. **We defined a strain as predominant if it represented >50% of isolates. ***If a second strain was also identified during the season, we also considered it predominant if it represented >25% of isolates. Predominant H3N2 year.
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Where: A 0 = intercept; A 1 = coefficient associated with month T, and; B 1 and B 2 = coefficients associated with seasonal fluctuations in deaths; e i is the error. We subtracted the predicted events during the influenza season from the number of events documented by Ministerio de Salud de la Nació n to quantify the excess events we associated with influenza infection. We assumed the excess R&C events would approximate the totality of influenza-associated hospitalizations and deaths.
We divided excess events during the influenza season by the census population to quantify the annual incidence of influenza-associated P&I and R&C hospitalization and deaths. We used the estimates from the Serfling model, which are stratified by age and sex, in a Poisson regression to explore whether excess in mortality and hospitalizations varied significantly by year, sex, and age <65 or ‡65 years.
Results

Laboratory-confirmed influenza season
During 2002-2009, Argentina tested 258 040 respiratory specimens of which 19 672 were positive for influenza (annual median 1%) (Figure 1) . Typically, the influenza season started each year during May, peaked during July and ended in October. We assumed this May through October epidemic period as the time when excess P&I and R&C case-patients could be potentially associated with influenza illness. (Figures 2 and 3A) . We estimated that the average influenza-associated mortality rate was 6AE0 ⁄ 100 000 person-years (95% CI 4AE1-8AE0 ⁄ 100 000 person-years) using P&I diagnostic codes and 21AE4 ⁄ 100 000 person-years (95% CI 11AE9-30AE8 ⁄ 100 000 person-years) using R&C codes (Table 1) . Figures 3B and 4) . We estimated that the average influenza-associated hospitalization rate was 2AE0 ⁄ 10 000 person-years (95% CI 0AE7-3AE2 ⁄ 10 000 personyears) using P&I diagnostic codes and 5AE7 ⁄ 10 000 personyears (95% CI 2AE9-8AE5 ⁄ 10 000 person-years) using R&C codes (Table 2) .
Anticipated, observed, and excess P&I and R&C deaths
Anticipated, observed, and excess P&I and R&C hospitalizations
Influenza-associated mortality and hospitalization rates by age, sex, and year
Influenza-associated P&I and R&C mortality and hospitalization rates were associated with the year of the influenza epidemic, and the age and sex of the patients (P < 0AE001 for each comparison). Influenza-associated mortality rates 
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were higher among men aged ‡65 years (average P&I rate = 37 ⁄ 100 000 person-years, R&C rate = 171 ⁄ 100 000 person-years) than among women aged ‡65 years (average P&I rate = 36 ⁄ 100 000 person-years, R&C rate = 136 ⁄ 100 000 person-years); and higher among men aged <65 years (average 2 ⁄ 100 000 person-years P&I rate and R&C rate = 4 ⁄ 100 000 person-years) than women aged <65 years (1 ⁄ 100 000 person-years P&I rate and R&C rate = 2 ⁄ 100 000 person-years). Influenza-associated mortality and hospitalization P&I and R&C rates were also higher among all age groups during 2007 when influenza A (H3N2) was the predominant virus in circulation (e.g., 34AE2 ⁄ 100 000 person-years influenza-associated R&C deaths and 8AE4 ⁄ 10 000 person-years R&C hospitalizations) compared with years in which with influenza A H1N1 or B influenza viruses were predominant (e.g., 11AE4-23AE4 ⁄ 100 000 person-years influenza-associated R&C deaths and 3AE9-6AE3 ⁄ 10 000 person-years R&C hospitalizations) (P < 0AE001). In 2009, when influenza A H1N1pdm was first introduced into Argentina, persons aged <65 years had higher influenza-associated R&C rates of death (8 ⁄ 100 000 person-years) than they did during periods of seasonal influenza (3 ⁄ 100 000 person-years) (P < 0AE001).
Discussion
During 2002-2009, we estimated that influenza contributed to an average of approximately 2000-9000 deaths and 8000-23 000 hospitalizations in Argentina (lower figures based on P&I, higher on R&C). R&C mortality rates among adults ‡65 ranged from 136 to 171 ⁄ 100 000 person-years versus 2-4 ⁄ 100 000 person-years among persons aged <65 years. This disparity justifies Argentina's policy to target persons aged 65 years or older for annual influenza vaccination. The only year during which persons aged <65 years were disproportionately affected by influenza was 2009, during the pandemic. 16 Of note, when influenza A (H3N2) was the predominant circulating influenza virus subtype, higher mortality rates were observed among all age groups. 6, 7, 17, 18 Our findings are similar to those of other studies in Argentina and the Americas and may underscore the value of collecting standardized virology and epidemiology surveillance data. 1, 12 For example, our mortality rates are similar to those estimated in Argentina during 1992-1999, 6 ,7 in neighboring Brazil, 19 and in the United States. 1 Our influenza-associated hospitalization rates during the pandemic are similar to those estimated using a multiplier model from three sentinel cities in Argentina (2.4 (95% CI 2.0-2.8) per 10 000 person-year). 20 In addition, our hospitalization rates are similar to seasonal influenza rates estimated in the United States (e.g., 1979-2001) and in other countries. 2, 3, 17 These influenza-associated hospitalizations and deaths may be associated with a costly economic burden. Such findings, based on virology and epidemiology data, are an important step in assessing the influenza disease and economic burden and determining the potential value of influenza vaccine.
It is known that other viruses, including respiratory syncytial virus, co-circulate with influenza viruses and cause substantial morbidity and mortality. Viral surveillance in Argentina, which is overrepresented by pediatric samples, demonstrated co-circulation of respiratory syncytial virus during each of the May through October influenza seasons. Therefore, a proportion of outcomes that we attributed to influenza infections were likely associated with respiratory syncytial virus infections, particularly among the 21% of hospitalized patients and 0AE1% of deaths aged <2 years of age. In addition, our estimates do not account for likely We assumed the excess respiratory and circulatory events during the influenza season approximate the totality of the annually influenza-associated mortality. We considered excess deaths (difference between observed and predicted) to be significant only if observed deaths exceeded the upper 95% confidence interval of the predicted deaths.
associations between temperature and wintertime increases in mortality. Our hospitalization data included only government-operated hospitals. While this includes the majority of Argentina's hospitalizations, it nevertheless is an underestimate of the total number of national hospitalizations. Therefore, the rates estimated in this study should be validated in future investigations using different methodologies, such as Poisson regression or multiplier models that 
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may better differentiate the contribution of individual viral pathogens to respiratory and circulatory disease.
3,20
Conclusion
Our findings suggest that similar to neighboring Brazil, Argentina annually had thousands of influenza-associated deaths and hospitalizations, particularly among the elderly. Our findings also suggests the value of standardized, reliable and integrated epidemiologic and viral surveillance needed to quantify influenza disease burden and useful in exploring the effectiveness of pharmaceutical (e.g., influenza vaccine and antiviral drugs, such as oseltamivir) and non-pharmaceutical interventions (e.g., hand washing and respiratory hygiene campaigns) aimed at preventing mortality and morbidity as a result of influenza illness. For example, Argentina and regional influenza vaccine policy may benefit from influenza-associated economic burden studies to determine how much is being spent as a result of influenza illness and to explore the potential value of expanding targeted influenza vaccine use and coverage. We assumed the excess respiratory and circulatory events during the influenza season approximate the totality of the annually influenza-associated mortality. We only considered difference between observed and predicted deaths (the excess deaths) to be significant if observed deaths exceeded the upper 95% confidence interval of the model.
